We will rely on you to help lend your voice and support the biotechnology industry.
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
BIO International ConventionJune 3-6, 2019
BIO World Congress on Industrial Biotechnology and Ag TechJuly 8-11, 2019
BIO Industry Analysis Reports >>
Save. Advocate. Connect. Join Us.
A listing of all BIO members and subsidiaries.
February 11 - 12, 2019 | New York, New York
Vyriad is a clinical stage biopharmaceutical company established to realize the full potential of oncolytic viruses to impact cancer, alone or in combination with immune-oncology agents. The company is developing multiple unique viral platforms, focusing on systemic delivery, single cycle therapy and noninvasive tracking of the infection in treated patients using proprietary reporter gene technologies. The company has a broad technology base, dominating intellectual property position, and a superior lead clinical asset with proven clinical trials execution capability and in-house GMP manufacturing coming on stream in 2019. The early clinical data sets from ongoing Phase 1 trials are compelling and will be summarized in the presentation.